Daniela holds a PhD in Clinical Psychology from The University of Edinburgh, United Kingdom, a MSc in Health Psychology and a BSc in Clinical Psychology. Her work has been focused on vulnerability to psychopathology and early identification and intervention in psychosis.
SIR-Spheres radiation microspheres shrank the tumors of a significantly larger number of liver cancer patients than the standard-of-care chemotherapy Nexavar (sorafenib), according to a Phase 3 clinical trial. The microspheres, which ... Read more
Albireo Pharma has secured two new patents from the U.S. Patent and Trademark Office (USPTO) for its lead drug candidate A4250 to treat liver diseases such as nonalcoholic steatohepatitis (NASH). Boston-based Albireo has reported promising ... Read more
Inventiva’s drug candidate IVA337, currently in Phase 2 studies for both non-alcoholic steatohepatitis (NASH) and systemic sclerosis (SSc), has shown a good safety profile in monkeys, according to a 12-month non-human primate ... Read more
A large observational study is looking at how doctors manage people with nonalcoholic steatohepatitis (NASH) or nonalcoholic fatty liver disease (NAFL). TARGET PharmaSolutions is conducting the study in collaboration with the biopharmaceutical ... Read more
Bozitinib (CBT-101) suppresses the growth of human liver tumors in a laboratory environment, according to its maker, CBT Pharmaceuticals. The oral therapy works by targeting a faulty protein signaling pathway ... Read more
Conatus Pharmaceuticals updated participants at two New York medical conferences this month on its efforts to develop emricasan, which has been shown to improve manifestations of chronic kidney disease. The San ... Read more
CymaBay Therapeutics has named Sujal Shah as interim president and CEO following the retirement of Harold Van Wart, PhD. Robert Wills, PhD, will serve as executive chairman during this transition phase. ... Read more